Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloid Leukaemia

The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy

Bone Marrow Transplantation volume 26, pages 1037–1043 (2000)Cite this article

Abstract

Results in 164 patients who underwent allogeneic marrow transplantation following busulfan and cyclophosphamide over a 15 year period were analyzed. Age (median 37, range 14–66 years) did not significantly affect the incidence of graft-versus-host disease (GVHD), but patients who received methotrexate with cyclosporine had a significantly lower incidence (P = 0.002) of chronic GVHD compared to those who received methylprednisolone with cyclosporine. Hepatic veno-occlusive disease (VOD) occurred less frequently in chronic phase patients (P = 0.002) and in those transplanted shortly after diagnosis (P = 0.001). Five year leukemia-free survival (LFS) for the entire group was 49% (95% CI 41–57%). For 102 patients who underwent transplantation in chronic phase, results were significantly improved by transplantation at a short interval following diagnosis, particularly within 3 months (P = 0.01), by the use of methotrexate and not corticosteroids for GVHD prevention (P = 0.03), and by use of HLA-identical sibling donors (P = 0.01). Age was not a significant adverse prognostic factor and transplantation was successfully performed in individuals up to age 66. Allogeneic transplantation in CML, including older patients and those with unrelated donors, can be most safely and effectively performed shortly after diagnosis. Bone Marrow Transplantation (2000) 26, 1037–1043.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Goldman JM . Chronic myeloid leukemia: new strategies for cure Education Program American Society of Hematology 1997 pp 1–7

  2. Sawyers CL . Chronic myeloid leukemia New Engl J Med 1999 340: 1330–1340

    Article  CAS  PubMed  Google Scholar 

  3. Lee SJ, Anasetti C, Horowitz MH, Antin JH . Initial therapy for chronic myelogenous leukemia: playing the odds J Clin Oncol 1998 16: 2897–2903

    Article  CAS  PubMed  Google Scholar 

  4. Gale RP, Hehlman R, Zhang M-J et al . for the German CML Study Group Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia Blood 1998 91: 1810–1819

    CAS  PubMed  Google Scholar 

  5. Horowitz MM, Rowlings PA, Passweg JR . Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry Bone Marrow Transplant 1996 17: (Suppl. 1) S5–S6

    PubMed  Google Scholar 

  6. van Rhee F, Szydlo RM, Hermans J et al . for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1997 20: 553–560

    Article  CAS  PubMed  Google Scholar 

  7. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia Blood 1994 84: 4368–4373

    CAS  PubMed  Google Scholar 

  8. Goldman JM, Szydlo R, Horowitz MM et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase Blood 1993 82: 2235–2238

    CAS  PubMed  Google Scholar 

  9. Buckner CD, Clift RA . Timing of allogeneic marrow transplants for patients with chronic myeloid leukemia Bone Marrow Transplant 1995 15: (Suppl. 1) S203–S206

    Google Scholar 

  10. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplantation from unrelated donors for patients with chronic myeloid leukemia New Engl J Med 1998 338: 962–968

    Article  CAS  PubMed  Google Scholar 

  11. Faderl S, Talpaz M, Estrov Z, Kantarjian HM . Chronic myelogenous leukemia: biology and therapy Ann Intern Med 1999 131: 207–219

    Article  CAS  PubMed  Google Scholar 

  12. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353

    Article  CAS  PubMed  Google Scholar 

  13. Tutschka PJ, Copelan EA, Klein J . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382–1388

    CAS  PubMed  Google Scholar 

  14. Copelan EA, Grever MR, Kapoor N, Tutschka PJ . Marrow transplantation following busulfan and cyclophosphamide for CML in accelerated or blastic phase Br J Haematol 1989 71: 487–491

    Article  CAS  PubMed  Google Scholar 

  15. Biggs JC, Szer J, Crilley P et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy 2 Blood 1992 80: 1352–1357

    CAS  PubMed  Google Scholar 

  16. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood 1994 84: 2036–2043

    CAS  PubMed  Google Scholar 

  17. Devergie A, Blaise D, Attal M et al . for The French Society of Bone Marrow Graft (SFGM) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan–cytoxan versus cytoxan–total body irradiation as preparative regimen: a report from The French Society of Bone Marrow Graft (SFGM) Blood 1995 85: 2263–2268

    CAS  PubMed  Google Scholar 

  18. Klein JL, Avalos BR, Belt P et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy Bone Marrow Transplant 1996 17: 479–483

    CAS  PubMed  Google Scholar 

  19. Sahebi F, Copelan E, Crilley P et al. Unrelated allogeneic bone marrow transplantation using high dose busulfan and cyclosphosphamide (Bu-Cy) for the preparative regimen Bone Marrow Transplant 1996 17: 685–689

    CAS  PubMed  Google Scholar 

  20. Mehta J, Powles RL, Mitchell P et al. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning Bone Marrow Transplant 1994 13: 583–587

    CAS  PubMed  Google Scholar 

  21. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255–267

    Article  CAS  PubMed  Google Scholar 

  22. Ringden O, Remberger M, Ruutu T et al. for the Nordic Bone Marrow Transplantation Group Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia Blood 1999 93: 2196–2201

    CAS  PubMed  Google Scholar 

  23. Kantarjian HM, Deisseroth A, Kurzrock R et al. Chronic myelogenous leukemia: a concise update Blood 1993 82: 691–703

    CAS  PubMed  Google Scholar 

  24. Gluckberg H, Storb R, Fefer A et al. Clinical manifestation of graft-versus host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  Google Scholar 

  25. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man Am J Pathol 1978 91: 545–570

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Clark JG, Crawford SW, Madtes DK, Sullivan KM . Obstructive lung disease after allogeneic marrow transplantation Ann Intern Med 1989 111: 368–376

    Article  CAS  PubMed  Google Scholar 

  27. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  28. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966 50: 163–170

    CAS  PubMed  Google Scholar 

  29. Cox DR . Regression models and life tables J Roy Stat Soc 1972 34: 187–220

    Google Scholar 

  30. Roth MS, Antin JH, Ash R et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplantation for chronic myelogenous leukemia Blood 1992 79: 276–282

    CAS  PubMed  Google Scholar 

  31. Radich JP, Gehly G, Gooley T et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients Blood 1995 85: 2632–2638

    CAS  PubMed  Google Scholar 

  32. Elmaagacli AH, Beelen DW, Opalka B et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow Blood 1999 94: 384–389

    CAS  PubMed  Google Scholar 

  33. Gratwohl A, Hermans J, Niederwieser D . Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation Bone Marrow Transplant 1993 12: 509–516

    CAS  PubMed  Google Scholar 

  34. Applebaum FR, Clift R, Radich J et al. Bone marrow transplantation for chronic myelogenous leukemia Semin Oncol 1995 22: 405–411

    Google Scholar 

  35. Clift RA, Storb R . Marrow transplantation for CML: the Seattle experience Bone Marrow Transplant 1996 17: (Suppl. 3) 51–53

    Google Scholar 

  36. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M . Interferon-α therapy for chronic myelogenous leukemia Am J Med 1995 99: 402–411

    Article  CAS  PubMed  Google Scholar 

  37. Hochhaus A, Hehlmann R, Kolb HJ et al. and the German CML Study Group Mannheim, Germany. The outcome of allogeneic bone marrow transplantation is strongly influenced by early discontinuation of interferon-alpha pretreatment in patients with chronic myeloid leukemia Blood 1998 92: 495a (Abstr.)

    Google Scholar 

  38. Gibbs JP, Gooley T, Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 1–6

    Google Scholar 

  39. Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients J Clin Oncol 1996 14: 1484–1494

    Article  CAS  PubMed  Google Scholar 

  40. Copelan EA, Penza SL . Preparative regimens for stem cell transplantation. In: Hoffman R, Benz EJ Jr, Shattil SJ et al (eds) Hematology. Basic Principles and Practice, 3rd edn Churchill Livingstone: New York 1999 pp 1628–1642

    Google Scholar 

  41. Storb R, Pepe M, Anasetti C et al. What role for prednisone in prevention of acute graft-vs-host disease in patients undergoing marrow transplants? Blood 1990 76: 1037–1045

    CAS  PubMed  Google Scholar 

  42. Copelan EA, Biggs JC, Avalos BR et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia J Clin Oncol 1992 10: 237–242

    Article  CAS  PubMed  Google Scholar 

  43. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42

    CAS  PubMed  Google Scholar 

  44. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060

    CAS  PubMed  Google Scholar 

  45. Grochow LB . The role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 1993 20: (Suppl. 4) 18–25

    CAS  PubMed  Google Scholar 

  46. Andersson BS, Fernandez H, Cagnoni P et al. IV busulfan, cyclophosphamide (BuCy) and hemopoietic stem cells for non-Hodgkin's lymphomas (NHL) Proceedings of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem BMT Meetings, Keystone Resort, CO, February 28–March 6 1999 2: p 3 (Abstr.)

  47. Vaughan WP, Cagnoni P, Fernandez H et al. Pharmacokinetics of intravenous busulfan in hematopoietic stem cell transplantation (HSCT) Proceedings of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem BMT Meetings, Keystone Resort, CO, February 28–March 6 1999 78: p 22 (Abstr.)

Download references

Acknowledgements

We thank referring physicians, our housestaff and nursing staffs, and Norma Haas for the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Program, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA

    EA Copelan, SL Penza, PJ Elder, MB Tighe, SA Ezzone, MD Scholl, PS Belt & BR Avalos

  2. Department of Pathology, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA

    KS Theil

  3. Department of Pharmacy, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA

    TP Bechtel

  4. Biostatistics Program, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA

    DC Young

Authors
  1. EA Copelan
    View author publications

    Search author on:PubMed Google Scholar

  2. SL Penza
    View author publications

    Search author on:PubMed Google Scholar

  3. KS Theil
    View author publications

    Search author on:PubMed Google Scholar

  4. PJ Elder
    View author publications

    Search author on:PubMed Google Scholar

  5. TP Bechtel
    View author publications

    Search author on:PubMed Google Scholar

  6. MB Tighe
    View author publications

    Search author on:PubMed Google Scholar

  7. SA Ezzone
    View author publications

    Search author on:PubMed Google Scholar

  8. MD Scholl
    View author publications

    Search author on:PubMed Google Scholar

  9. PS Belt
    View author publications

    Search author on:PubMed Google Scholar

  10. DC Young
    View author publications

    Search author on:PubMed Google Scholar

  11. BR Avalos
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Copelan, E., Penza, S., Theil, K. et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplant 26, 1037–1043 (2000). https://doi.org/10.1038/sj.bmt.1702689

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702689

Keywords

This article is cited by

Search

Advanced search

Quick links